Flood Law Group to Sponsor ByettaCancerLawsuit.org
Flood Law Group is announcing that it is sponsoring ByettaCancerLawsuit.org, a new website aimed at helping Byetta users in learning about the potential risk of pancreatic cancer.
(PRWEB) June 26, 2013
Flood Law Group, a national litigation firm, is sponsoring ByettaCancerLawsuit.org, an online resource aimed at helping people in learning about the increased risk for pancreatic cancer in people taking the Type 2 diabetes medication Byetta (exenatide).
According to Flood Law Group, anyone who is diagnosed with pancreatic cancer and who has a history of taking Byetta may qualify for financial compensation.
Dr. Sidney Wolfe, the Director of Public Citizen’s Health Research Group, issued a statement on March 22, 2013, urging the FDA to remove Byetta and other similar drugs from the market. In the statement Wolfe cited a new study conducted by Drs. Alexandra Butler and Peter Butler of the University of California-Los Angeles (UCLA) and their colleagues at UCLA and the University of Florida, which provides evidence that patients who take the diabetes medications Byetta, Januvia and Victoza have a greater chance of developing pancreatic cancer than those who are not taking the medications.*
Patients with pancreatic cancer usually don’t know it until the cancer has reached an advanced stage. Symptoms usually don’t appear in the early stages, but when they do occur, they can include:
- Upper abdominal pain that radiates to the back
- Jaundice (yellowing of the skin and eyes)
- Loss of appetite
- Weight loss
- Blood clots**
According to Flood Law Group, it is sponsoring ByettaCancerLawsuit.org to help spread awareness about the risk of pancreatic cancer. If you or someone you love has been diagnosed with pancreatic cancer and is taking or has taken Byetta, you may qualify for financial compensation.
To learn more or to schedule a consultation with a defective drug lawyer at Flood Law Group, call 1-888- 836-2483 or visit ByettaCancerLawsuit.org.
For the original version on PRWeb visit: http://www.prweb.com/releases/byetta-cancer-website/MM/prweb10875140.htm